Abstract
Two hundred and fifty patients with acute myeloid leukaemia (AML) were randomized between 2 regimens of chemotherapy: TRAP and BARTS III. Overall, patients randomized to TRAP, which was the more intensive of the 2 regimens, fared slightly better (P = 0.06) than those on BARTS III. However, the improvement in survival associated with more intensive chemotherapy was substantial only for patients who had favourable prognostic features at presentation, such as a normal total leucocyte count, or absence of palpable liver, or, especially, age under 40. Indeed, for patients under 40, those allocated to the more intensive regimen (TRAP) lived considerably longer than those allocated to BARTS III (P less than 0.002) while for patients over 40 there was no material difference in survival between patients on the 2 protocols. It thus appears that intensive chemotherapy is likely to be more effective when favourable prognostic features are recorded.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Burge P. S., Prankerd T. A., Richards J. D., Sare M., Thompson D. S., Wright P. Quality and quantity of survival in acute myeloid leukaemia. Lancet. 1975 Oct 4;2(7936):621–624. doi: 10.1016/s0140-6736(75)90111-7. [DOI] [PubMed] [Google Scholar]
- Crowther D., Bateman C. J., Vartan C. P., Whitehouse J. M., Malpas J. S., Fairley G. H., Scott R. B. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J. 1970 Nov 28;4(5734):513–517. doi: 10.1136/bmj.4.5734.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crowther D., Powles R. L., Bateman C. J., Beard M. E., Gauci C. L., Wrigley P. F., Malpas J. S., Fairley G. H., Scott R. B. Management of adult acute myelogenous leukaemia. Br Med J. 1973 Jan 20;1(5846):131–137. doi: 10.1136/bmj.1.5846.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977 Mar 5;1(8010):497–499. doi: 10.1016/s0140-6736(77)91366-6. [DOI] [PubMed] [Google Scholar]
- Harris A. L. Leukostasis associated with blood transfusion in acute myeloid leukaemia. Br Med J. 1978 May 6;1(6121):1169–1171. doi: 10.1136/bmj.1.6121.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harris R., Zuhrie S. R., Freeman C. B., Taylor G. M., MacIver J. E., Geary C. G., Delamore I. W., Hull P. J., Tooth J. A. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions. Br J Cancer. 1978 Feb;37(2):282–288. doi: 10.1038/bjc.1978.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rees J. K., Sandler R. M., Challener J., Hayhoe F. G. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer. 1977 Dec;36(6):770–776. doi: 10.1038/bjc.1977.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spiers A. S., Goldman J. M., Catovsky D., Costello C., Galton D. A., Pitcher C. S. Prolonged remission maintenance in acute myeloid leukaemia. Br Med J. 1977 Aug 27;2(6086):544–547. doi: 10.1136/bmj.2.6086.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stavem P., Gjemdal T., Ly B. Prolonged remission maintenance in acute myeloid leukaemia. Br Med J. 1977 Sep 24;2(6090):831–831. doi: 10.1136/bmj.2.6090.831-a. [DOI] [PMC free article] [PubMed] [Google Scholar]